1195 - F-18 Flurodeoxyglucose Positron Emission Tomography (FDG PET) for the diagnosis of Alzheimer's Disease

Assessment No	1195
Application Name	F-18 Fluorodeoxyglucose positron emission tomography (FDG PET) for the diagnosis of Alzheimer’s disease
Assessment Type
Description Of Medical Service	FDG is a slightly radioactive form of glucose that can be safely injected into a patient. After 30 minutes a scan can then be performed with a PET camera, which takes approximately 15 minutes.
Description Of Medical Condition	Alzheimer’s disease is the most common cause of dementia. It is progressive and leads to severe disability and then morbidity – on average seven years from diagnosis. Symptoms of Alzheimer’s disease are present for several years before diagnosis and the pathological process that leads to the dementia of Alzheimer’s disease begins a decade or more before diagnosis.
Pre Assessment Meeting	22 March 2011
Stage 2 – Suitability for Assessment	14 October 2011
Lodgement of Proposed DAP	Awaiting Proposed DAP from Applicant
Stage 3 - 1st PASC (Draft DAP considered)
Stage 3 – Release for Public Comment (Consultation DAP)
Stage 3 - 2nd PASC (Final DAP)
Stage 4 - Submission of Collated Evidence
Stage 5 - ESC evaluation
Stage 6 - MSAC Appraisal
Stage 6 - MSAC advice
Stage 7 - Noting by Minister
Stage 8 - Implementation

Page currency, Latest update: 04 March, 2013